AGEN - Earnings call transcript Q4 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Agenus Inc. Fourth Quarter and Full Year 2023 Results Conference Call. Today's conference is being recorded. time, Zack like Relations. Armen, this conference turn At to over Head Instructions] I to would the [Operator of Investor go ahead. Please

Zack Armen

other today. this our website Thank for replay. I'd webcast thank and remind for will Today's you time and and time to among lines us that and call will statements on including you, being partnership plans statements, updates. data regarding our and call well commercial available as you be lines include like forward-looking is clinical for Audra, release development, regulatory as joining all opportunities

and These and for statements are subject to filings our risks. refer risks SEC to website available these on uncertainties, our you on details more we

Chief are me Klaskin, Dr. Finance. Robin be President Chief Christine Garo Dr. session. today of Steven the Vice will Adviser, Executive Yancey, Chief participating Dr. Joining Todd O'Day, in and Officer; Q&A Commercial Medical Strategic Officer; Taylor, and and Chairman Chief Armen, Officer; Dr.

Now in to I'd for like to highlight our and XXXX. speak XXXX our outlook Garo? over to to Garo to turn the call progress

Garo Armen

with very is gentlemen, past at made the much. and that share enthusiasm remarkable today, Ladies Genesis over gather it strides year. you the we Thank to great

testing and across types attention has XXXX, our and field from operational overall by achievements experts poised field. needs, rates journey durability program a impressive over of cornerstone potential milestones efficacy BOT/BAL in patients. The BOT/BAL colon in in excitement demonstrating and reached observed significant first XXX response Our in promising particularly cancer, where represented activity for and multiple innovation focus. we steadfast have are that has crucial notably leading of cancers pivotal cancer marked to medical Agenus sustained the milestones commitment garnered challenging In rigorous clinical undergone approval. been the oncology. with therapy our

in standard achieved treatments, the more patients have making note It our the meaningful. all enrolled essential is responses clinical to trials that exhausted available

balstilimab chemotherapy. year as past potential and or and immense of underscore the immune with the Botensilimab, achievements both therapy stand-alone combination a Our in potential in

All at of forums of will call. into a publication shortly, journals ongoing. this findings. the are the significance and presentation Dr. The scientific review in prestigious is O'Day providing our XP detailed data trials delve robustness and our currently testament clinical insights these of more data to X during

The resounding more, nonliver metastatic have the FDA the the urgent could need acknowledges in past transitions transformative MSS over and engaged for of work indications, from feedback Track Turn care. our over is X,XXX the year the by lead patient granted CRC with underscores impact the to new impact treatments refractory in designation Fast we it on which patients. our

a advancing on a As we filing. a phase for focus in is our our activities clinical critical journey, the approval regulatory squarely threshold of on accelerated potential spend and

are efforts for ensuring indication. XXXX, immediate is our rigorous directed objective strategy FDA's in track Our development regulatory align to standards. In that our a global strategies towards pursue fast the seamlessly our BOT/BAL with primary

as a Following initiate intend accelerated for application, our known BLA of license to with submission alignment biologics we otherwise potential FDA, approval. the the

the comprehensive Subsequently, To XXXX. Europe, our safety, EMA, the we to are achieve refractory as clinical in our a regulatory submit in objectives, pending European and package from pharmacology intensifying we regulatory data Agency, known that the and efficacy in provide MSS-CRC. to scientific BOT/BAL to in with advice authorities feedback regulatory Medicines plan efforts demonstrates

dosage to evaluate XXXX in was BOT/BAL's meticulously say, study and Our in or enrollment of Phase II completed its completed components. contribution the designed I should XXXX October

patient by indication. of population study a end XXXX, III Additionally, proposed initiating the of Phase we the anticipate our in

remains engagement to potentially progress patients. delivering altering treatments light to and as towards transparency we stakeholder commitment Our unwavering these

fast. remains patients our to the years immune enhance That's been day ago. to from mission cancer of lives power mission ahead, our Looking system the XXX of

course, Of portfolio dynamic leading agents. our BOT/BAL the in of charge today with

strategic transformative are exploring actively we [indiscernible] journey, To this partnerships.

yielded already for commencement study a the the BMS II have exemplified, TIGIT development with Agenus a BMS-XXXXXX. collaborations bispecific done Phase of ongoing to was discovered from This significant by example, licensed million returns, BMS. Our and triggered by the by milestone recent payment and it is was $XX antibody early

the have royalty We to generate ] O'Day additional term. and an will thus potential we for our $XXX revenues received $XXX million financing for prospective exploring this opportunities far. our from an pharmaceutical to of and assets million now Moreover, progressing core in efforts $XXX we've progress Furthermore, project a explore relatively so discussions noncore total collaboration million core monetize far. funding partners, made engaged further are several agreements eliminating with latest and overview findings the near the provide clinical with marketing [ development specifically groundbreaking we're in Dr. BOT/BAL. to of

cancer to your healing and for that you new Dr. treatment, Thank in in Together, hope continued we confidence patients a offers support era Agenus. are O'Day. one pioneering and worldwide.

Steven O’Day

to Garo. in Throughout Society new today that clinical XXXX comprehensive programs Oncology, our hosted ASCO presented a summary a press Gynecologic CTOS I Together our presented corporate Congress for program the our and ESMO October. all refer XXXX, nearly during our was provides and release GI, investigators BOT/BAL data GI of clinical key at updates. ESMO you, opinion we Thank development of development of you event from issued leaders, with at updates and

like from some year, to have of patients. we data updates Starting a opportunities with selection the transform which care our I'd of to highlights for safety. Today, last compelling the share

We to safety profile. continue observe a manageable

events study common per solid or of both per tumor balstilimab. milligrams kilo data XXXX adverse cut X kilo most Botensilimab, with of with these colitis. combination The were most in doses common and As milligram X of were our and the Ib diarrhea Phase May immune-related, from of

immuno-oncology are greater Grade the with both diarrhea mechanism findings or colitis action and These agents. of XX% in BOT patients. as X of treatment-related BAL of occurred consistent our

for CRC BAL, made progress. program development our to have BOT we where turning and Now significant

XXXX, overall response our expanded rate to October of the in during X% months median evaluable similar Ib rate Based cohort confirmed ranges our RESIs follow-up XX.X corporate our review, with had X%. of standard event in of latest patients XX%. response now and therapies XX of care treated on literature from population a Phase a As of update

XXXX. Medical patients available XXX data and showed XX our patients In cancer by overall data a in of BOT trial We XX-month doses for align XX with rate addition, at trial planned were second sufficient anticipate II Median data publicly the in X regulatory not half survival reached. with our time been line Phase has In allow with January of survival having in XX%. was dose from top the trial milligrams line [indiscernible] an Center. GI of treated To which colorectal overall Cornell balstilimab At year, milligram. maturation. investigator-sponsored this presented X at being ASCO of and conducted from

window near In after had of on treatment And during colorectal responses. X All setting. was were Surgery pathologic complete X even X a in colorectal patients performed MSI XX% initiation to tumor including XX patients immune-related of or with due therapy delayed more greater -- stable the cancer complete surgeries high immunotherapy. of pathologic during neoadjuvant responses delayed of average had interval X None opportunity importantly, the toxicities. the pathologic growth had complete out of no and patients MS responses. or weeks X of X

patients. colorectal events, treatment-related stable results for Grade were move opportunity particularly non-metastatic reversible. There treatment were potentially represent cancer. diarrhea paradigm IST XX currently additional therapy and important lines fatigue, adverse adding and into MS only early-stage an instances is X to of earlier which X the of These change This an

extends of combination designs plan immunotherapy of further to data, pivotal of of expansion therapy study X to we are agents, evaluating with patients prioritize data from to lastly, a ] which chemotherapy therapy. X pancreatic X Depending X neoadjuvant with studies. gemcitabine And on studies. as botensilimab and surgery in more Abraxane neoadjuvant reflective development and we reported on for weeks, the dosing The [ second-line triplet cancer, X timing and the is and traditional the

weeks chemotherapy, aggressive liver All X following We achieved a and and which and reductions. was at most reported. metasis. marker patients target of tumor patients sustained XX% of had had X confirmed X the all XX marked both data reported the the X a first-line time of the at response confirmation the X reductions XX% partial of regimen patients pending was lesion [indiscernible] achieving metastatic progressed with

preliminary Two and XX data other first showed anticipate stable patients available XX being combining cold half of this the botensilimab respectively. X-week of II study of early their results Phase in refractory in and at balstilimab tumor in disease or enrolling, scan tumors we botensilimab and reductions in the chemotherapy. randomized is year. currently A activity with either demonstrate clear setting second both disease, These with

limited provide standards current where team, support grateful patient to of families and patients We for the hope and offers outcomes committed this participants are trial And remain and stakeholders. of benefit. our improving

over to Christine call discuss the turn to I'll financials. Now

Christine Klaskin

Steven. Thank you,

For XXXX, or $XXX the year net and $XXX we per ended December recognized revenue million XX, incurred $X.XX a of loss million share. of

achieved of primarily XX, including or related $X.XX incurred fourth a our million revenue noncash recognized million we revenue of milestones the to $XX ended For Revenue loss agreements, quarter earned. $XX and share. December and net under collaboration XXXX, includes per royalties revenue

a cash, payment the we We discovered XXXX, ended Phase triggered BMS-XXXXXX, by which from a $XX bispecific milestone Agenus the antibody. with subsequent study year BMS $XX in to of million commencement million with January TIGIT received in II the

monetizing assets and future partnerships. in from and nonstrategic ongoing progressed milestones we've Additionally, royalties

further efforts expected the potential parties to through with call to parallel, I'll by These to anticipate now Accordingly, are X we're being we funded turn XXXX. partnership cash cash discussions proceeds In yield mid-XXXX. resources. pursuing biopharmaceutical our expand significant back Garo.

Garo Armen

and Steven Christine. you, Thank

patients course, As that look opportunities Agenus cancer the about in excited of XXXX. and we we're ahead, both

options. secures innovation. patients our also not Our value company enhanced through long-term that providing shareholder patients, on the but remains A continued steadfast centered enhanced with and treatment cancer mission only prosperity benefits indication of

us. years. a to our our advancements to our filing This a been will has their support. to expand for We Agenus shareholders, objective present continue to of application. and to our the our over license it more mission has our been heartfelt existence partners seeking the consent team It's unwavering commitment critical Innovation biologics package enduring year, many entire pioneering is growth, compelling for to be. been in FDA initiate gratitude paramount us data Agenus oncology and their a and than the for

make delivering threshold lives the you you transformative of ask. Thank they poised And for chemotherapy-free may with at we the invite the questions impact Audra? your any ultimate stand aim we treatment of attention. patients to journey, profound worldwide a very one and much a Together, options. time on now of

Operator

our at Instructions] [Operator Emily Bodnar from H.C. first We'll Wainright. take question

Emily Bodnar

CRC is study. on My first the one neoadjuvant

you're weeks. X that to the to X mentioned weeks from X extending You treatment period

there are curious longer could metrics think treatment So I may treatment think greater efficacy that you if you was certain a the with if period? how you and improve period impact could discuss

in on saying you're then also were And confirm outcomes. to if following And that mid-XXXX. their Could you second submission? believe previously I eventually patients MSS timing CRC. post the surgery question of the just And look BLA that surgical you at study

that now? like more So second is that looking still half [indiscernible]

Garo Armen

So the Emily, last submission. I'll start BLA with on the of timing the question

as is they're investors for guidance submission. to very specific planning the meet and with our on guided mid-year on us step So BLA we've before, we're the first giving their which doing FDA,

we and get the guidance of jump out of than will we meeting. So not to different that FDA gun provide want do that ahead what meeting

to more from with a much give able few think guidance only about months will I us, BLA bear we're be a you now, on talking our solution. specific that we So

Steven O’Day

like you to? would Garo me

Garo Armen

Neoadjuvant And has this he in [indiscernible] remarkable mentioned said in of new yesterday, exciting. fact, neoadjuvant the when advisers I to was data, and the data them reasons one been further. first the talking was conversation how very long-term because all of to thing adjuvant exciting very our you

Steven O’Day

not Emily, remarkable percentage Garo. was deep no the the patients period these in that weeks. in were MS-stable effective what was essentially has with cancer of results X surgeons you, colorectal I immune comfortable yes. regressions with X-week the Thank terms are window delay tumor given been therapy in which mean, of allowing And previously surgery.

X- will that over we that study period. the of do to anticipate a of allow extension And we responses. now the further see So X-week proper treatment deepening will time,

and outcomes we're to relapses. at post looking So that. study surgery surgical forward The is looking obviously

study. this be comprehensive a will So neoadjuvant

Operator

We'll go Securities. Mamtani next Riley at to Mayank B.

Mayank Mamtani

update. the comprehensive Appreciate

design? to data, able Phase just be II push should if we to what are have slight to makes or here durability could you maybe the about data OS comment And out on? III statistically mature the focused relating So is wanting sense Phase you MSS-CRC data, I if which thinking on you're on see the

for have timing any that on follow-ups. launching And also be regulatory III, you I meetings, maybe around thinking of And we then discussions a couple if aware that? comment can and of Phase should planned

Garo Armen

Yes.

we respond know, months said have you as October. we've first completed typically, we enrollment as And within patients of So X the before, dose. the XX% in of

So we get time get it's patients the we XX% by dose time May. the by readout responses, enrollment the you're sometimes when or on the about of November. talking the complete first And X-month

Now the the and so have data laterite needless all the started all outcomes to can we we process cleaning as possible. of as that say, soon up already provide of

data the So public is with the we the data the meeting, be very after to be and FDA on it of plan FDA next FDA appropriately. months meeting in our timing will the step making will because share close. data few generation this line then the first And top and

Mayank Mamtani

[indiscernible] Phase off that launch, III, design, on comment could timing,

Garo Armen

like you to please? take that, would Steven,

Steven O’Day

Phase with II, anticipate the the and is started potential in III Yes. substantially XXXX. I end our trial line be therapy mean Phase getting trial can it we by of enrolled date in the year, plans same so as a producer the at the that of

Mayank Mamtani

like much it of opportunity play Got than CRC comment discussions are also could what that doing and been a strategic more you're you've Garo, less about on but the how unlock maybe being your a does a with deal alignment bit areas or commitment Coco neoadjuvant then it. that it could comes more biopharma of the kind a And structure precise you before. looks Because obviously study. market, role? the long-term expands it you're prioritizing

Garo Armen

I very in way to any your question important think confidentiality. that a it's address evaluate

as have, talked couple you last we partnering for the know, So years. about BOT/BAL of

of enthusiastic an inquiries, discussions had And today. clinical patient our have course, in trial of Now prospective data explosive when have fraction investigators. we of course, started our with physicians data. to a we our the Fraction we And partners, the enrollment. had we of growth thanks

in mean months. I we enrollment, enrolled at, look X patients if II that trial example, record people. many a XXX is surprised which for you our has Phase than less

I of Now earlier, we've that expect, the treatments not radio reduction is cure biopharmaceuticals as when a companies. course, by fascination no. fair pharmaceutical there's with prospective result to biopharmaceutical do in and all talked that of and as experts. as that, question a well about cancer, weight ADCs. say often would all with of enthusiasm you of But I ADCs ask Amit, answer amount the

if only the know because term sure curing you slice thing don't And the don't occurred a cured the how clinically is cancer? of there a melanoma that we dicey [indiscernible] -- cancer do that. that it cancer. course, for of curing demonstrate patients. We fact called that we is Now how curing And very has is we're know term do you demonstrate know a product

restricted to But it's mostly been melanoma.

activation in of the is of course, important the fact, A development In [indiscernible] one was Now day pioneers of of that [indiscernible] specifically T the very binds attributes receptor cells. clinical CTLA-X. system, to of that in of the it one immune

it CTLA-X, so binds many things. also that we to botensilimab Now does but our other know

are hopeful, be botensilimab been will broader that what we Yervoy's has in hopeful melanoma. activity activity So than eventually,

we're course, And And resources question put about excited so a like-minded with balstilimab. doing of of and with going to that botensilimab makes it. that, the we're the partner be develop to that in will what

that our the first cancer once an our buy-in is of our kinds the of we filing, it, regulatory go and for patients, development explosive we botensilimab. the deserve is meaning it, expansion that that aim aim deserve for For get railway

And right that the the develop will but partner, be be is, deserves different indications we've of it, selected of way the be is total, activity. for in the us, some several denominators said that expansion next for remarkable the why course, just months would hopefully, partner for patients the patients XXX as activity. we X There because, product to in have know, remarkable this basis with of ways seen across about not no benefit Explosive you X it varying in developed. to the

think, hand, unfortunately, number And number on. slipped we have, I There take of now long are one active again, going time. on discussions. right discussions a that a So are active discussions these of a Christine

Our with taken shortage resulted has a discussion nearly in was significant that has years longest on a year. corporate partnership X

So that from a to just is going suggesting guidance I'm But partnership time. give these be things want year not I the that you now. to take

Mayank Mamtani

you're Could give can for Very maybe just helpful, just numbers refractory you what and and patient activity on have expecting cohort this or Garo. And maybe to second lastly half would that to update on lung, [indiscernible] the if in marketable data you some. your pancreatic mid pancreatic TKI lung talk

Garo Armen

ask this ask. if more either specific may address feel questions, to and free or have please I clarification Steven If you for Todd the question, to

Steven O’Day

Mayank. yes, So

In total, we trial a of accruing terms have Phase treat arm, that of expect concept. and XX pancreas, patients proof and actively we on to each XX trial, randomized III further is for

In expanded the We're terms This of data data, approximately the the is TKI lung cohort, release data as we've you press to patients. today. preliminary XX our in showing have maturing. said, we

You refractory X have and had have The half mature, report. data responses and We to to can of in the them of very see were year more data both the overall TKI second that patients. we'll continues population in patients complete.

Operator

Baird. Colleen Kusy to at go we'll Next,

Colleen Hanley

feedback just you prior Can outstanding of are think you some the items the comment to CRC filing? what need you do MSS FDA

Garo Armen

comp with Is alignments question, FDA to that BLA the potential the will filing? the what are

Colleen Hanley

Yes.

Garo Armen

Okay.

were the the arm. the also of trials trial we as of a well because very had example, course, it said small rapidly very to agency selection reference we want as for elements. go strategic us And a important moving, contribution of a dose and II trial to with the I earlier, was for first -- because to as we've Phase So decision enrolling go clinical we rapidly, and we of were made all, our

of arms. trial Now you, powered statistically is mind the show to between differentiation course, not this any

questions. However, designed to project optimist it is address the

us, to was you present to ask and the go this? agency and have you abstract What in come intelligent is we'll we so well, an to answer. be, if And that? The an question likely us, it a the the when answer to is question back form. us What give for them is data

And that the the so we that gain present mature decision we all us to wait for to FDA. where able in had get to order point, to to to made compelling the a to strategic a would package be point we data until --

waiting somewhat we reason middle So year. which the that's until the the matures, are this data why of will begin before

And as you know, little procedurally with discussion in a time. package takes requesting meetings or meetings being granted and a comprehensive a data

for month. we meeting So having a on and the very around on meeting or planning plus sometime are minus asking soon planning midyear, the

Colleen Hanley

the then And Great. pancreatic next there? data look like from the follow-up development Phase in development have What I just midyear. program. would path know we'll on towards II the the one trial approval steps

Garo Armen

For the pancreatic?

Colleen Hanley

Yes.

Garo Armen

Okay.

So in we in through trial. trial with Phase patients just package that I CRC our and the FDA will patients XXX II the to Phase is the recap, approximately indication go the XXX our data for

for cohort Now the trial. and I is the at expansion for ask to result us elucidate next us, of step the the from with will existing the pancreatic, randomized more. step next data day But Dr. Steven to look

time. short the is of unfortunately, [indiscernible] remarkable to Furthermore, the second-line then to pancreatic standard of and rates of for is for experience range information As of activity response them published patients period patients observed relapsed. full XX% according these in the And you within care these a not know, now standard the is and that XX%. cancer relapse the And patients curative. we care, treated were with in fury some

being reference about with XX% duration. short rates XX% talking to ARM we're in very So being response

fact remind be patients have data tumor a course, level of a presented has seen we're that in now we doing. you, not high should is responses, given in the size us this of counts. expanded, patients classified a patients the but all have what have tumor, but of the all is the a Now shrinkage seen confidence of them are that their trial that and seen small, drop shrinkage their cancer significant all denominator And in

a XX randomized data initial the think data So is smaller of then for results the confirm we the for indication. in from we a believe, I a And the enrolled, this them potential now. patients denominator have will approval the as requirements and to That the reason to FDA maturing. I have for around trial accelerated matures go and we patients, ask

have also, will our said may we approval. as Now are go other we indications potentially for that before, colleagues that have indications

again, patients, smaller initial be these in denominator is, denominator. the in One results will of smaller cancer, we a on example, trials compelling subject expansion But our that are investigate. EGFR results so of the to will to confirm all mutant for lung

and the subset have that fact, of there's we verify our we that reduction in size trials. that in a mutation to expand seen In specific tumor earlier EGFR profound will cohort understand

a that population will we thereby for with in of be the population report what product for patient that J&J size is tenth larger sales. is what similar that So a for in billions pursuing patient of estimates may to did And saw is I the about the be last their a specific.

these there are response the of that patient applies biomarker-driven subsets specific in by for facto opportunities that of populations high that different small new to format So lung and trials patient that yield pursue lung are also very will populations and very a de applies adjuvant. cancer will typically, and certain identification that cancer, rates driven we

and sparing XXs would have particularly lower and And lower and a that for we when in rectum to patient is horrible. debilitating about we're patients. in about that trial debilitating this that patient. tumor going surgery is surgery particular Removal colon a sparing, I surgeries to the case, would a debilitating outcome, neoadjuvant what population. in that's radical younger and our you them the colon seen left cautious it's -- Particularly. if direct surgery for yield you're is all XXs, be your we of the in talk have But talking mean, be

new our tremendous that strategy, believe with a prevent that's can adjuvant opportunity. we if So we

options all of at course, and and more, these looking tuned. we're stay of So

Colleen Hanley

follow-up, I quick very helpful. really One That's can. if

Just for the on to proceed Or adjuvant -- will of next the that all will those potential neoadjuvant new allow altogether? surgery study, to setting the surgery? get patients

Garo Armen

Well okay.

So I'll to response, complete refuse surgery. I one O'Day elaborate, know least patient have after but let at a

have tricky Now approved reasons the of course, situation. yet. patient that's cannot We physician now. hence, product considerations. by indication to an And for don't that that a But surgery, in refuses a [indiscernible] their right life. It's ethical it's got we be And a ethical made if recommendation

seeing are we stress kind everything of course, ethical so I that be in has you to that But don't a regulatory potential done well-being guidance. to develop. And jeopardize that properly want the be appropriate has fact done everything with an of way And locations. the to

Operator

go We'll at Phipps Blair. to William next Matthew

Matthew Phipps

just when II half think said seems patient, you you be like data that have from do given this PFS colorectal data the So by study, the could in for that Phase point possible. progress curious, you'll second in the

Garo Armen

relative Todd, difference regulatory patients that? interval think experts, OS in OS any is our PFS have gold less PFS to I these will to standard, you Steven, refer a so. is but that do I So the such much short comments on is

Todd Yancey

Yes. and talk. ahead, Steve, go I'll

Steven O’Day

when last yes, survival preliminary in rate, response, of duration as obviously, they PFS course were over mature from the mean, response have patients their the crude. -- from of Matt, year and we'll they these I

prolonged disease to the survival stable it's response drives clearly, drive obviously, composite what a curve. Garo's endpoint. of and point, response and So But duration is

and gold our duration So survival. ultimately, are obviously standard response response the end then points primary

Matthew Phipps

follow-up why the the May, or in or curious, just meet I you line results, Garo, like with disclose guess, met been to that? why least that guess, wait months at top has guess of not whether I after some by till something least, endpoint X say at And not FDA the given or I indication point.

Garo Armen

currency FDA would regulatory not public strictly data we're It's ready before I be present make to the think that break to our that if to it appropriate FDA.

Matthew Phipps

you'll assume FDA after make I disclosures from And publicly receiving then meeting. that minutes the Okay.

bit adding time for So that. a little of

Operator

move next, [indiscernible] to Jefferies.. Kelly And we'll

Unknown Analyst

on for Sara is This Kelly.

on question matter. one So quick

next the update, given data for of shown in X% So you've patients response our

Garo Armen

can Your line, voice faint there's and is the crackling coming speak some you to the in very microphone. closer if

Unknown Analyst

How about now?

Garo Armen

better. Yes,

Unknown Analyst

Got it. Okay.

cancer question one update. the just So on lung

we you stage data be development? in into be the overall And to Given the expected if plan advance cancer? efficacy see can update next for believe forward of us expect to BMS remind you've in disclosure other shown the the program you data just so, should this going response wondering, partner need also to well? wanted TIGIT I what would as on lung the next data year confirm. Wondering XXXX? the what what is patients. would And also Just

Garo Armen

Sure.

of here. So a couple things

we the down the cancer, slowed overall as in you On know, trial. lung enrollment

to about we're having data our that significant what talking I So significant response, doing level. significant us, now, outcome. responses, complete when had responses patients right a at subsets have rapid dissected That, complete of is the and I'm say looked -- responses at low dose

as process of identifiable subsets the said proceed, how patients. we would now with of in I earlier, So defining biomarker those we're

year, a our from data the so next regard step going mature And but for patients be in this be that to cancer balance to by data that's cancer, the randomized time cohorts With preliminary mature coming maybe larger that's midyear, by we in some data happen more pancreatic data -- data We'll very coming have year-end. will quickly. lung data mature would of of in trial have but melanoma. more

in And our responses provide course, We data the you substantially shortly after in colon sarcoma. meetings. sustainability regulatory will cancer more of will of see

Unknown Analyst

helpful. Super

Operator

like Garo are over no there for to conference remarks. would questions to turn further the I Armen time. closing this at And

Garo Armen

stay sure think were they our first commitment a resources our stakeholders all, very in to your great because of make we've as you and want are And to are you the thank as for in covered deal unique not past. here, we're Audra, very Thank I attentiveness much, fantastic abundant insured and a focused, much just I and actually. sort questions, of very make environment, where we that of sure that

so And but do things thing forces industry rationally. companies, not because more just us, good to a it that's the maybe

efficiency. delivering So we with on intend outcomes

both each to product, a are to from this. in We a terrific well poised from commercial to launch as as a have we do team potentially perspective, category be able perspective, CMC

that, through we Education our competent so our addition that to eventually medicines. well physicians very processes drive education. that In we affairs will can of have a as medical very, system, assembled prescribe patients, team regulators as the

So important of components. these all we to are very retending

We Thank we at in very are communicate attentiveness time. your an and in young company will large a you small, that old and ways. with for next sense many appropriately the much company you

Operator

for you And this call. today's concludes your Thank conference participation.

You may now disconnect.

Agenus (AGEN) 14 Mar 242023 Q4 Earnings call transcript